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Abstract
Background: To study whether maternal serum hyperglycosylated human chorionic gonadotropin (hCG-h)
improves first trimester prediction of pre-eclampsia when combined with placental growth factor (PlGF),
pregnancy-associated plasma protein-A (PAPP-A) and maternal risk factors.
Methods: Gestational-age-adjusted concentrations of hCG, hCG-h, PlGF and PAPP-A were analysed in serum
samples by time-resolved immunofluorometric assays at 8–13 weeks of gestation. The case–control study included
98 women who developed pre-eclampsia, 25 who developed gestational hypertension, 41 normotensive women
with small-for-gestational-age (SGA) infants and 177 controls.
Results: Of 98 women with pre-eclampsia, 24 women developed preterm pre-eclampsia (diagnosis < 37 weeks of
gestation) and 13 of them had early-onset pre-eclampsia (diagnosis < 34 weeks of gestation). They had lower
concentrations of PlGF, PAPP-A and proportion of hCG-h to hCG (%hCG-h) than controls. In receiver-operating
characteristics (ROC) curve analysis, the area under the curve (AUC) for the combination of PlGF, PAPP-A, %hCG-h,
nulliparity and mean arterial blood pressure was 0.805 (95% confidence interval, CI, 0.699–0.912) for preterm
pre-eclampsia and 0.870 (95% CI 0.750–0.988) for early-onset pre-eclampsia. Without %hCG-h the AUC values were
0.756 (95% CI 0.651–0.861) and 0.810 (95% CI 0.682–0.938) respectively. For prediction of gestational hypertension,
the AUC for %hCG-h was 0.708 (95% CI 0.608–0.808), but for other markers the AUC values were not significant.
None of the AUC values were significant for the prediction of SGA infants in normotensive women.
Conclusions: First trimester maternal serum %hCG-h tended to improve prediction of preterm and early-onset
pre-eclampsia when combined with PlGF, PAPP-A and maternal risk factors.
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Background
Pre-eclampsia occurs in 2–8% of all pregnancies. It is a
significant cause of maternal morbidity and mortality,
especially in developing countries. Pre-eclampsia also in-
creases the risk of pre- and perinatal complications such
as intra-uterine growth restriction (IUGR), low birth
weight, preterm birth and perinatal death [1].
So far there has been no therapy for pre-eclampsia other
than delivery [1]. However, several recent studies suggest
that early-onset (diagnosis before 34 weeks of gestation)
and severe forms of pre-eclampsia might be prevented by
daily low-dose aspirin when started by the 16th week of
gestation in mothers at risk [2, 3]. Therefore, early predic-
tion of pre-eclampsia has become important.
As the development of the placenta and its vasculature
are often impaired in pre-eclampsia, maternal serum
concentrations of placenta-derived factors may be useful
in identifying women at risk. Maternal serum concentra-
tions of placental growth factor (PlGF), a member of the
vascular endothelial growth factor (VEGF) –family, have
been shown to be lower in the first and second trimes-
ters in women who will develop pre-eclampsia as com-
pared to controls [4–8]. Maternal serum concentrations
of soluble fms-like tyrosine kinase-1 (sFlt-1), an antagon-
ist of PlGF, are elevated in the second trimester in
women with subsequent pre-eclampsia and seem to pre-
dict short-term complications of pre-eclampsia in estab-
lished disease [5, 9, 10]. Pregnancy-associated plasma
protein-A (PAPP-A) is used clinically for first trimester
screening for Down’s syndrome [11], and low concentra-
tions in maternal serum have also been associated with
early-onset pre-eclampsia [4, 12].
The placenta produces various forms of human chori-
onic gonadotropin (hCG) including hyperglycosylated
hCG (hCG-h), which is the major form of hCG in early
pregnancy [13]. Elevated concentrations of hCG-h have
been observed in gestational trophoblastic diseases [14]
and suggested to be associated with increased cytotro-
phoblast activity [15–17]. We have recently shown that
the proportion of hCG-h to total hCG (%hCG-h) at 8–
13 weeks of gestation predicts pre-eclampsia with mod-
erate accuracy, i.e. with 56% sensitivity at 90% specificity
[12]. Low concentrations of hCG-h in mid-trimester ma-
ternal urine, but not in serum have also been associated
with subsequent pre-eclampsia [18, 19].
Clinical risk factors include nulliparity, a history of pre-
eclampsia, multiple gestation, obesity and chronic hyper-
tension [20–22]. Furthermore, reduced uterine artery blood
flow, high first trimester uterine artery pulsatility index (PI)
and resistance index (RI), detected by Doppler ultrasound,
indicate increased risk of pre-eclampsia [4, 23].
Earlier studies have combined marker concentrations
and clinical risk factors in an attempt to predict subse-
quent pre-eclampsia already in the first trimester. Thus
far the most promising combinations in early pregnancy
have been those including maternal characteristics, mater-
nal blood pressure and PlGF and/or PAPP-A, and in many
studies also uterine artery Doppler PI. Furthermore, these
algorithms give the best prediction rates for early-onset
pre-eclampsia [4, 6]. Some studies have found that inclu-
sion of sFlt-1 concentrations improves the prediction rates
in the cases of late-onset pre-eclampsia [8, 24], but others
have found sFlt-1 to not predict pre-eclampsia during the
first trimester [7, 9, 25].
The aim of this study was to investigate whether a
combination of first-trimester serum %hCG-h with PlGF,
PAPP-A and maternal clinical risk factors improves the
diagnostic accuracy for prediction of pre-eclampsia.
Methods
Patients
Altogether 12,615 pregnant women gave blood samples while
attending first trimester screening for Down’s syndrome at
8–13 weeks of gestation in the Kuopio University Hospital
region in Finland between April 1st, 2008 and December 31st,
2010. Gestational age was determined by measuring the
crown-rump length of the fetus by ultrasound. Approval to
carry out the study was given by the Ethical Research
Committee of Kuopio University Hospital. Written informed
consent was obtained from all participants.
Criteria of the American College of Obstetricians and
Gynecologists (ACOG) were used to define pre-eclampsia:
systolic blood pressure ≥ 140 mmHg or diastolic blood
pressure ≥ 90 mmHg in two separate measurements at
least 6 h apart after 20 weeks of gestation in a previously
normotensive woman with a 24-h urinary protein excre-
tion of ≥ 0.3 g [26]. Superimposed pre-eclampsia was de-
fined as onset of proteinuria ≥ 0.3 g/ 24 h in women with
chronic hypertension or hypertension before 20 weeks of
gestation [26]. Exclusion criteria were multiple gestation or
major congenital anomalies.
According to hospital records, 273 women were diag-
nosed with pre-eclampsia. After exclusion of patients with
missing samples (n = 109), multiple gestation (n= 10) or un-
verified diagnosis according to definition by ACOG (n= 56),
98 women with pre-eclampsia were included in the study.
According to the onset of symptoms, two subgroups were
analysed separately: early-onset pre-eclampsia (diagnosis <
34 weeks of gestation) and preterm pre-eclampsia (diagno-
sis < 37 weeks of gestation). Pre-eclamptic women giving
birth to small-for-gestational-age (SGA) infants (age- and
sex-adjusted birth weight below the 10th percentile [27])
were also analysed separately. In addition, the study included
normotensive women with SGA infants and women with
gestational hypertension (elevated blood pressure as defined
above without proteinuria). We selected controls among
women who according to hospital records did not develop
pre-eclampsia, gestational hypertension or did not give birth
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to SGA infants as described in our previous study [12]. Of
the 427 controls in the previous study, 177 serum samples
were available for analysis for this study.
Laboratory techniques
Blood was allowed to clot for 30 min at room temperature
before separation of serum by centrifugation. Serum sam-
ples were stored at +4 °C and analysed for PAPP-A within
five days according to manufacturer’s instructions (Perkin
Elmer Wallac Oy, Turku, Finland). The samples were then
stored at −20 °C until analysis of hCG (Perkin Elmer Wallac
Oy, Turku, Finland) and hCG-h by time-resolved fluoroim-
munoassay as described previously [12]. Concentrations of
PlGF were determined in February 2012 according to
manufacturer’s instructions using the AutoDELFIA assay
(Perkin Elmer Wallac Oy, Turku, Finland). Intra- and inter-
assay coefficients of variation (CV) were <1.8% and <3.7%
(PAPP-A), 1.8% (mean) and < 8.8% (hCG), 2.2% and <10.8%
(hCG-h) and 4.8% and <8.8% (PlGF). Variation was deter-
mined in ten aliquots of two serum pools analysed either in
the same or in consecutive runs. The calibrators for PAPP-
A covered the range 10–2000 mU/L, for hCG 5–30600
pmol/l, for hCG-h 9–9000 pmol/l and 6–4920 pg/mL for
PlGF. Serum samples were diluted 5-fold prior to assay of
PAPP-A, 100-fold prior to assays of hCG and hCG-h. This
eliminates interference by complement in the hCG-h assay
[28]. The PlGF assay measures free PlGF but not PlGF
bound to sFlt-1 [29].
Statistical analysis
The concentrations of PlGF were converted to multiples of
median (MoM) values using principal component regression
analysis based on the equation “median PlGF log = 0,153*
gestational weeks - 0,1157”. Concentrations of hCG-h,
PAPP-A and %hCG-h were adjusted for gestational age by
converting the concentrations to MoM values as described
previously [12]. After log-transformation, the MoM values
were normally distributed according to the Kolmogorov-
Smirnov test.
Differences between cases and controls were analysed
by ANOVA and post hoc comparisons for controls by
Dunnett’s test. For continuous variables the Mann–
Whitney U test was used to compare clinical character-
istics of the groups. Comparison of dichotomized vari-
ables was done with the x2 test. Multivariate linear
regression analysis was used to study correlations be-
tween clinical characteristics and biomarker concentra-
tions. Logistic regression was used to analyse the
contributions of different maternal risk factors and
serum markers to the risk of pre-eclampsia. Receiver-
operating characteristic (ROC) curve analysis was used
to estimate the diagnostic accuracy, which was expressed
as the area under the curve (AUC). SPSS version 21 was
used to carry out statistical analysis. The results were
considered statistically significant when P values were <
0.05. Results were expressed as medians and 95% confi-
dence intervals (CIs) or interquartile range (IQR) or
mean ± SD, whichever was most appropriate.
Study power
The power of the study was calculated according to our
previous data. Power analysis was based on the difference
of gestational-age-adjusted PlGF concentrations in women
with subsequent pre-eclampsia and controls at 14–17
weeks of gestation [19]. For 98 cases of pre-eclampsia and
177 controls the power was 100%, for 13 cases of early-
onset pre-eclampsia it was 82% and for 24 cases of preterm
pre-eclampsia it was 97% with a two-tailed P value of 0.05.
Results
Of the 98 pre-eclamptic women included in this study,
24 had preterm pre-eclampsia including the 13 with
early-onset pre-eclampsia. Twenty of the pre-eclamptic
women gave birth to SGA infants (Table 1). Of the
patients with early-onset disease 10/13 (77%) gave birth
before 34 weeks of gestation. Delivery before 37 weeks
occurred in 19/24 (79%) of the women with preterm pre-
eclampsia. In addition, the study included 41 normoten-
sive women with SGA infants and 25 women with gesta-
tional hypertension.
Clinical characteristics
Women in the various groups were comparable regarding
first-trimester body mass index (BMI), smoking status,
and gestational age at sampling. Women with subsequent
gestational hypertension were slightly older than the con-
trols. Nulliparity was more common in all affected groups
than in controls. Chronic hypertension and type 1 diabetes
were more common in pre-eclamptic women than in con-
trols. First trimester systolic blood pressure was higher in
women with either pre-eclampsia or SGA without hyper-
tension. Clinical characteristics of the women enrolled are
shown in Table 1.
PlGF, hCG- h and PAPP-A concentrations
The median MoMs of PlGF concentration were lower in
women with subsequent preterm pre-eclampsia or pre-
eclampsia with SGA infants, as compared to controls. The
median MoMs of %hCG-h were lower in all the affected
groups, except for normotensive women with SGA infants
as compared to controls [12]. Median MoMs of PAPP-A
were lower in women with subsequent pre-eclampsia,
early-onset pre-eclampsia and preterm pre-eclampsia in
comparison to the control group [12] (Table 2).
AUC values for prediction of pre-eclampsia
The AUC values for prediction of early-onset pre-eclampsia
were 0.692 (P= 0.021) for PlGF, 0.764 (P = 0.001) for %hGC-
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h, 0.783 (P = 0.001) for PAPP-A and 0.885 (P < 0.0001) for
their combination (Table 3 and Fig. 1a). For prediction of
preterm pre-eclampsia the AUC values were 0.680 (P =
0.004), 0.699 (P= 0.002), 0.714 (P = 0.001) and 0.830 (P <
0.0001), respectively (Table 3 and Fig. 2a). The correspond-
ing AUC values for pre-eclampsia with SGA infants were
0.653 (P= 0.025), 0.682 (P= 0.008), 0.634 (P= 0.049) and
0.747 (P < 0.0001) (Table 3 and Fig. 3a). For prediction of
gestational hypertension the AUC value for %hCG-h was
0.708 (95% CI 0.608–0.808, p= 0.001), although for other
markers the AUC values were not significant. The AUC
values were not significant for the prediction of SGA infants
in normotensive women (data not shown).
The AUC values for combinations of the different
markers and maternal risk factors were determined by
backward stepwise logistic regression analysis. The risk of
pre-eclampsia was calculated with the formula eL / (1 + eL),
where e = 2.718, L = −4.887–1.060 * log PlGF MoM - 9.524
* log PAPP-A MoM - 7.194 * log %hCG-h MoM+ 0.034 *
mean arterial blood pressure (MAP) + 1.615 * parity (0 =
multipara, 1 = nullipara) or eL / (1 + eL), where e = 2.718, L
= −5.617–1.257 * log PlGF MoM – 8.821 * log PAPP-A
MoM - 7.126 * log %hCG-h MoM+ 0.026 * mean arterial
blood pressure (MAP) + 1.736 * parity (0 =multipara, 1 =
nullipara) + 0.024 * maternal age + 0.026 * BMI + 0.065 *
smoking (0 = no smoking, 1 = smoking).
Combination of %hCG-h, PAPP-A, PlGF, MAP and nul-
liparity gave an AUC value of 0.870 (P < 0.0001) for early-
onset pre-eclampsia. When PlGF was left out of the ana-
lysis the AUC value was 0.868 (P < 0.0001) while the AUC
value was 0.810 (P < 0.0001) when %hCG-h was removed
(Table 3 and Fig. 1b). The respective AUC values for pre-
term pre-eclampsia were 0.805, 0.803 and 0.756 (P <
0.0001) (Table 3 and Fig. 2b). For prediction of pre-
eclampsia with SGA infants the respective AUC values
were 0.845, 0.843 and 0.826 (P < 0.0001) (Table 3 and
Fig. 3b). Finally, combining %hCG-h, PAPP-A, PlGF,
MAP, nulliparity, age, BMI and smoking gave an AUC
value of 0.864 (P < 0.0001) for early-onset pre-eclampsia
(Table 3 and Fig. 1b), 0.806 (P < 0.0001) for preterm pre-
eclampsia (Table 3 and Fig. 2b) and 0.854 (P < 0.0001) for
pre-eclampsia with SGA infants (Table 3 and Fig. 3b).
Table 1 Clinical characteristics of the women enrolled
Characteristic Controls
n = 177
PE
n = 98a
Early-onset PE
n = 13a, a1
Preterm PE
n = 24a
SGA and PE
n = 20a
GH
n = 25
SGA
n = 41
Maternal age (years) 29 ± 5 28 ± 6 29 ± 4 29 ± 5 30 ± 6 32 ± 5c 29 ± 5
Nullipara - n (%) 78 (44) 78 (80)b 10 (77)c 17 (71)c 19 (95)b 17 (68)c 29 (71)c
Smokers - n (%) 16 (9) 8 (8) 2 (15) 3 (13) 1 (5) 1 (4) 7 (17)
GA at sampling (weeks) 10.2 ± 0.9 10.4 ± 0.9 10.6 ± 0.8 10.5 ± 0.8 10.4 ± 1 10.1 ± 0.7 10.4 ± 0.8
BMI (kg/m2) 25 ± 5 26 ± 5 27 ± 6 26 ± 6 25 ± 5 27 ± 6 23 ± 5
Blood pressure (mmHg)
Syst. 1st trimester 120 ± 12 125 ± 15c 133 ± 22c 130 ± 20c 122 ± 12 127 ± 13c 123 ± 12c
Diast. 1st trimester 74 ± 10 78 ± 11c 80 ± 14 79 ± 15 76 ± 11 78 ± 11 76 ± 8
Proteinuria (g/24 h) ND 2.5 (0.7–3.2) 4.8 (1.5–8.5) 4.1 (1.4–5.1) 2.7 (1.3–5.1) ND ND
HELLP - n (%) 0 7 (7)b 1 (8)b 3 (13)b 1 (5)c 0 0
Chronic disease - n (%) 22(12) 21 (21)c 5 (38)c 7 (29)c 5 (25) 4 (16) 8 (20)
Hypertension - n (%) 0 7 (7)b 1 (8)b 2 (8)b 2 (10)b 0 0
Diabetes - n (%) 1(0.6) 4 (4)c 3 (23)b 4 (16)b 0 0 1 (2)
Gestational DM - n (%) 28 (16) 21 (21) 2 (15) 3 (13) 1 (5) 6 (24) 8 (20)
Diagnosis <34 wk -n (%) 0 (0) 13 (13) 13 (100) 13 (54) 2 (10) 2 (8) 0 (0)
Delivery - weeks 40.1 ± 1.1 38 ± 2.9b 32.4 ± 3b 34.3 ± 3.1b 40 ± 2b 39.4 ± 1.7c 40 ± 0.9
Birth weight (kg) 3.6 ± 0.4 3.0 ± 0.8b 1.6 ± 0.6b 2.1 ± 0.8b 2.3 ± 0.5b 3.2 ± 0.6b 2.9 ± 0.2b
SGA - n (%) 0 20 (20)b 2 (15)b 6 (25)b 20 (100)b 8 (32)b 41 (100)b
Umbilical artery pH 7.24 ± 0.09 7.22 ± 0.09 7.22 ± 0.1 7.22 ± 0.09 7.21 ± 0.1 7.22 ± 0.09 7.23 ± 0.08
Placental weight (g) 620 ± 120 530 ± 150b 370 ± 100b 430 ± 160b 410 ± 110b 500 ± 130b 540 ± 100b
The reported numbers are mean ± standard deviation, amount (percent) or median (interquartile range)
Abbreviations: PE pre-eclampsia, early-onset PE diagnosis made < 34 weeks of gestation, preterm PE diagnosis made <37 weeks of gestation (women with
early-onset pre-eclampsia included as a subgroup), GH gestational hypertension, SGA small-for-gestational-age (sex- and age –adjusted birth weight < 10th
percentile), GA gestational age, ND not determined, HELLP hemolysis, elevated liver enzymes and low platelet count
aSome patients may belong to more than one of these subgroups. a1Women with early-onset pre-eclampsia are included in the subgroup of preterm
pre-eclampsia. bP < 0.001 compared with controls, or cP < 0.05 compared with controls analysed by Mann Whitney U test for continuous variables or x2 test for
categorical variables
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Correlations of marker concentrations with clinical
characteristics
The concentrations of PlGF (r = 0.181) and PAPP-A (r =
0.473) increased and those of %hCG-h (r = −0.124) de-
creased with advancing pregnancy. The concentrations
of PlGF correlated positively with PAPP-A (r = 0.315)
and negatively with %hCG-h (r = −0.198). The concen-
trations of PAPP-A correlated negatively with maternal
BMI (r = −0.191). No statistically significant correlation
was observed between BMI and the concentrations of
PlGF or %hCG-h. PAPP-A also correlated positively with
nulliparity (r = 0.173). Smoking correlated with higher
concentrations of PlGF (r = 0.322). None of the markers
correlated with maternal age, chronic diseases, gesta-
tional diabetes, first trimester blood pressure, level of
proteinuria or placental or infant weight.
Discussion
As a novel finding we here show that combining %hCG-h
with PlGF, PAPP-A and maternal clinical risk factors includ-
ing nulliparity and first trimester MAP tended to improve
prediction of pre-eclampsia as compared to prediction
models without %hCG-h. The association of these models,
− i.e. lower first-trimester maternal serum concentrations of
PlGF and PAPP-A - with subsequent early-onset or preterm
pre-eclampsia and pre-eclampsia with SGA infants has also
been shown earlier [4–6, 8, 30–32].
Low first trimester serum PlGF concentrations have
been suggested to reflect the placental pathology in pre-
eclampsia, i.e. in impaired cytotrophoblastic differenti-
ation and invasion and spiral artery formation [33, 34],
seen in early-onset or preterm pre-eclampsia; or pre-
eclampsia with placental insufficiency or SGA [4, 6, 8,
35]. Also, an imbalance between PlGF and its antagonist
sFlt-1 is seen in pre-eclampsia, as administration of sFlt-
1 causes pre-eclampsia-like symptoms in pregnant rats
[36], and elevated serum concentrations of sFlt-1 are
seen from 18 gestational weeks onwards in women with
subsequent pre-eclampsia [5, 7, 9]. It is worth noting,
though, that changes in maternal serum PlGF and sFlt-1
concentrations are not specific for pre-eclampsia but ra-
ther a response to placental stress [37].
We found that smoking correlated with elevated PlGF
concentrations, which is in line with earlier observations
[38]. Exposure of placental cells in culture to smoke ex-
tracts decreases expression of sFlt-1 that may cause eleva-
tion of free PlGF in serum [39]. Nicotine stimulates PlGF
production in endothelial cells and facilitates endothelial
cell migration and tube formation that can be suppressed
by sFlt-1 in vitro [40]. It may be speculated that these bio-
chemical mechanisms lie behind the negative association
between smoking and incidence of pre-eclampsia.
A low %hCG-h seems to be associated with the risk of
pre-eclampsia during the first trimester but, as we earlier
showed, its ability to predict pre-eclampsia may disappear
after the 13th week of gestation [19]. hCG-h is secreted by
extravillous cytotrophoblasts and has been suggested to
promote cytotrophoblast invasion [15–17]. Thus, a low
Table 2 Serum marker concentrations
Controls
n = 177
PE
n = 98
Early-onset (<34 wk) PE
n = 13a, a1
Preterm (<37 wk) PE
n = 24a
SGA and PE
n = 20a
GH
n = 25
SGA
n = 41
PlGF
Median 28.4 26.2 25.8 25.3 23.0 26.4 31.3
95% CI 26.7–30.0 24.6–27.3 20.3–28.6 20.3–26.7 20.5–28.4 21.5–27.8 26.9–34.0
Median MoM 1.00 0.98 0.94 0.95b 0.97b 0.98 1.01
95% CI 0.97–1.02 0.95–1.00 0.88–1.00 0.89–1.00 0.88–0.99 0.92–1.04 0.98–1.05
%hCG-h
Median 12.4 10.2c 8.1c 9.1c 10.6c 10.6b 11.6
95% CI 11.7–13.0 8.9–11.1 4.5–9.4 7.3–10.8 7.0–11.6 8.6–11.4 9.7–12.7
Median MoM 1.01 0.92c 0.84c 0.86c 0.85b 0.90b 0.97
95% CI 0.96–1.02 0.88–0.97 0.70–0.94 0.79–0.97 0.81–0.97 0.82–0.93 0.89–1.06
PAPP-A
Median 648 567 503 507 499 330b 642
95% CI 582–757 463–657 209–769 354–702 337–904 250–690 494–794
Median MoM 1.01 0.97b 0.93b 0.93b 0.96 0.95 0.98
95% CI 0.99–1.03 0.95–1.00 0.81–0.95 0.86–0.97 0.90–0.98 0.91–1.00 0.93–1.02
PE pre-eclampsia, early-onset PE diagnosis made < 34 weeks of gestation, preterm PE diagnosis made < 37 weeks of gestation, SGA small-for-gestational-age
(sex- and age –adjusted birth weight < 10th percentile), GH gestational hypertension, CI confidence interval
aSome patients may belong to more than one of these subgroups. a1 Women with early-onset pre-eclampsia are included in the subgroup of preterm
pre-eclampsia. bP < 0.05 or cP < 0.001 as compared to controls analysed by ANOVA with post hoc Dunnett's test after logarithmic transformation
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Table 3 Area under the curve (AUC) values for MoM values of the markers
PE
n = 98
Early-onset (<34 wk) PE
n = 13a, a1
Preterm (<37 wk) PE
n = 24a
SGA and PE
n = 20a
PlGF
AUC 0.558 0.692b 0.680b 0.653b
95% CI 0.486–0.705 .0.557–0.826 0.572–0.7880 0.519–0.788
%hCG-h
AUC 0.636c 0.764b 0.699b 0.682b
95% CI 0.566–0.705 0.622–0.907 0.577–0.821 0.550–0.815
PAPP-A
AUC 0.580b 0.783b 0.714b 0.634b
95% CI 0.507–0.653 0.656–0.910 0.612–0.849 0.500–0.769
PlGF, %hCG-h, PAPP-Ad
AUC 0.689c 0.885c 0.830c 0.747c
95% CI 0.622–0.756 0.804–0.966 0.747–0.913 0.624–0.869
PAPP-A, PlGF, MAP, nulliparityd
AUC 0.750c 0.810c 0.756c 0.826c
95% CI 0.689–0.811 0.682–0.938 0.651–0.861 0.733–0.919
%hCG-h, PAPP-A, MAP, nulliparityd
AUC 0.776c 0.868c 0.803c 0.843c
95% CI 0.717–0.834 0.749–0.986 0.696–0.910 0.760–0.925
%hCG-h,PAPP-A, PlGF, MAP, nulliparityd
AUC 0.776c 0.870c 0.805c 0.845c
95% CI 0.718–0.835 0.753–0.988 0.699–0.912 0.763–0.927
%hCG-h, PAPP-A, PlGF, MAP, nulliparity, age, BMI, smokingd
AUC 0.779c 0.864c 0.806c 0.854c
95% CI 0.721–0.837 0.740–0.988 0.697–0.914 0.771–0.937
PE pre-eclampsia, early-onset PE diagnosis made < 34 weeks of gestation, preterm PE diagnosis made < 37 weeks of gestation, SGA small-for-gestational-age
(sex- and age –adjusted birth weight < 10th percentile), CI confidence interval, MAP mean arterial pressure, BMI body mass index
aSome patients may belong to more than one of these subgroups. a1Women with early-onset pre-eclampsia are included in the subgroup of preterm
pre-eclampsia. bP < 0.05 or cP < 0.001 as compared to controls by ROC analysis. d Based on a risk calculation derived from logistic regression analysis
Fig. 1 Receiver operating characteristics curves for early-onset pre-eclampsia
Receiver operating characteristics (ROC) curves for the MoMs of serum markers (a) and their combinations with maternal clinical risk factors (b)
for the prediction of early-onset pre-eclampsia (diagnosed <34 weeks of gestation)
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%hCG-h may reflect the impaired cytotrophoblastic differ-
entiation and invasion in the first trimester seen in pre-
eclampsia [33, 41, 42]. This may explain the independent
predictive value of %hCG-h in pre-eclampsia, as PlGF
reflects the imbalance of the angiogenetic milieu and
%hCG-h the failure of cytotrophoblast invasion.
We found that PlGF MoM was lower in women with
subsequent preterm pre-eclampsia, pre-eclampsia with SGA
infants and in women who developed early-onset disease
compared to controls, but statistical significance was not
reached in the last group. This may be due to the small
sample size as only 13 women developed early-onset pre-
eclampsia giving a power of 82% for the study in this setting.
We therefore also analysed a group of 24 women that devel-
oped preterm pre-eclampsia, which gave a power of 97%.
Gestational hypertension shares clinical risk factors with
pre-eclampsia, and one-third of the patients progress to
pre-eclampsia [43, 44]. In line with previous studies, we
found that PlGF and PAPP-A concentrations did not differ
between women who developed gestational hypertension
and controls [10, 45]. However, like in pre-eclampsia,
%hCG-h was lower in gestational hypertension than in
controls. This may indicate that %hCG-h is a more sensi-
tive marker of placental pathology than PlGF or PAPP-A,
as similar endothelial dysfunction and impaired cytotro-
phoblastic invasion that are seen in pre-eclampsia have
also been observed in gestational hypertension, only in
lesser magnitude [43, 44]. However, pre-eclampsia is a
clinically more severe disease as it is associated with more
adverse outcomes than gestational hypertension [44].
Fig. 2 Receiver operating characteristics curves for preterm pre-eclampsia
Receiver operating characteristics (ROC) curves for the MoMs of serum markers (a) and their combinations with maternal clinical risk factors (b) for the
prediction of preterm pre-eclampsia (diagnosed <37 weeks of gestation)
Fig. 3 Receiver operating characteristics curves for pre-eclampsia with SGA
Receiver operating characteristics (ROC) curves for the MoMs of serum markers (a) and their combinations with maternal clinical risk factors (b)
for the prediction of pre-eclampsia with SGA
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Normotensive women having SGA infants have been
shown to have lower PAPP-A concentrations in some
studies [46–49] but, however, in our study we did not
observe any differences between cases and controls in
PAPP-A or other markers. The explanation might be that
SGA infants in our study represented a very mild form of
SGA having mean delivering time at term and mean birth
weight only slightly below 10th percentile. Concentrations
of PlGF in normotensive women with SGA infants have
been shown to be lower already in the first trimester as
compared to controls [50], but in other studies differences
in PlGF concentrations have only been present in the sec-
ond trimester [51] or not at all [52].
Algorithms combining clinical factors such as nullipar-
ity, maternal age, high BMI and elevated first trimester
blood pressure are useful for predicting the risk of pre-
eclampsia [6, 20]. When we combined these clinical char-
acteristics with maternal serum concentrations of PlGF,
PAPP-A and %hCG-h, the best AUCs were obtained by
combining nulliparity and first trimester MAP with the
serum markers. As in earlier studies, we observed the
highest AUC value (0.870) in early-onset pre-eclampsia.
For PlGF alone the AUC value was lower (0.692). In the
study of Crovetto et al. the AUC value for first trimester
prediction of early-onset pre-eclampsia was 0.788 for PlGF
alone and 0.945 for an algorithm combining clinical risk
factors, MAP, mean uterine artery PI and PlGF [8]. The
role of uterine artery PI is probably of importance in
explaining the high AUC value. Goetzinger et al. created a
first trimester prediction model with clinical risk factors,
uterine artery PI and PAPP-A, and reached an AUC value
of 0.76 [53]. The study populations of Crovetto and Goet-
zinger are similar to ours.
Other studies have found that in first trimester screen-
ing algorithms the uterine artery PI has been one of the
strongest predictive factors for early-onset pre-eclampsia
[6, 8, 54]. Doppler ultrasound measurements were not
available in our study population because these are not
routinely measured in the first trimester screening
appointments in Finland. Uterine artery PI measurements
would probably have enhanced the predictive accuracy of
our algorithm. On the other hand, Doppler ultrasound is
sensitive to inter-observer variation, requires advanced
ultrasound equipment and thorough training of the
screening personnel. Thus, an algorithm based on marker
concentrations and clinical risk factors might be more re-
producible and cost-effective than an algorithm including
Doppler ultrasound. In present study smoking, maternal
age and BMI were less significant in logistic regression
analysis, but we also included them in our algorithm since
in different study settings they have been shown to have
predictive value [6, 35].
A recent systematic review and meta-analysis by Zhong
et al. found that the predictive values of first trimester
PlGF and PAPP-A were better for early-onset pre-
eclampsia as compared to late-onset pre-eclampsia, which
is in line with our findings. PlGF was superior to other
single markers (PAPP-A, hCG and placental protein 13)
but these first trimester markers had low accuracy for
prediction of pre-eclampsia. Importantly, the predictive
accuracy of first trimester markers was not poorer than
that of second trimester markers [55]. In our study we ob-
served that PAPP-A was higher in nulliparous than in
multiparous women, which is an unexplained finding also
observed in an earlier study [56].
In Finland most pregnant women attend combined first
trimester screening for Down’s syndrome, and thus our
study population was unselected and represented a wide
spectrum of women of different ages and from different
backgrounds, which is a strength of our study. There were
differences in the clinical characteristics between the sub-
groups, but this was taken into account in the statistical
analysis and found not to affect the results. The small
number of women with early-onset pre-eclampsia as well
as the fact that uterine artery Doppler measurements were
not available are acknowledged weaknesses. Despite these
the power of the study was sufficient, and with our
algorithm we reached relatively high AUC-values for
prediction of early-onset and preterm pre-eclampsia.
In two recent meta-analyses low-dose aspirin treatment
has been shown to reduce the risk of early-onset and se-
vere pre-eclampsia in high-risk mothers [2, 3]. ACOG has
recently recommended that only a detailed medical his-
tory should be used for screening of pre-eclampsia until
studies show that aspirin or other interventions reduce
the incidence of pre-eclampsia for women at high risk
based on first-trimester predictive tests [57]. Therefore,
large prospective studies are needed to evaluate whether
screening with combinations of PlGF, PAPP-A, %hCG-h
and maternal clinical characteristics will be useful for se-
lection of candidates for aspirin treatment.
Conclusions
First-trimester serum PlGF, PAPP-A and maternal clinical
risk factors have been shown to predict early-onset pre-
eclampsia. This is the first study to show that combining
%hCG-h with PlGF and other above mentioned factors en-
hance the accuracy to predict early-onset pre-eclampsia.
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